450 related articles for article (PubMed ID: 19808874)
21. Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.
Graziani G; Lisi L; Tentori L; Navarra P
Exp Suppl; 2022; 113():295-350. PubMed ID: 35165868
[TBL] [Abstract][Full Text] [Related]
22. Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma.
Boutros C; Chaput-Gras N; Lanoy E; Larive A; Mateus C; Routier E; Sun R; Tao YG; Massard C; Bahleda R; Schwob D; Ibrahim N; Khoury Abboud RM; Caramella C; Lancia A; Cassard L; Roy S; Soria JC; Robert C; Deutsch E
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819972
[TBL] [Abstract][Full Text] [Related]
23. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
[TBL] [Abstract][Full Text] [Related]
24. CTLA-4 antibody ipilimumab negatively affects CD4
Rosskopf S; Leitner J; Zlabinger GJ; Steinberger P
Cancer Immunol Immunother; 2019 Aug; 68(8):1359-1368. PubMed ID: 31332464
[TBL] [Abstract][Full Text] [Related]
25. Ipilimumab: controversies in its development, utility and autoimmune adverse events.
Weber J
Cancer Immunol Immunother; 2009 May; 58(5):823-30. PubMed ID: 19198837
[TBL] [Abstract][Full Text] [Related]
26. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
O'Mahony D; Morris JC; Quinn C; Gao W; Wilson WH; Gause B; Pittaluga S; Neelapu S; Brown M; Fleisher TA; Gulley JL; Schlom J; Nussenblatt R; Albert P; Davis TA; Lowy I; Petrus M; Waldmann TA; Janik JE
Clin Cancer Res; 2007 Feb; 13(3):958-64. PubMed ID: 17289891
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
Bakacs T; Mehrishi JN; Moss RW
Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
[TBL] [Abstract][Full Text] [Related]
28. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Snyder A; Makarov V; Merghoub T; Yuan J; Zaretsky JM; Desrichard A; Walsh LA; Postow MA; Wong P; Ho TS; Hollmann TJ; Bruggeman C; Kannan K; Li Y; Elipenahli C; Liu C; Harbison CT; Wang L; Ribas A; Wolchok JD; Chan TA
N Engl J Med; 2014 Dec; 371(23):2189-2199. PubMed ID: 25409260
[TBL] [Abstract][Full Text] [Related]
29. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
Callahan MK; Wolchok JD; Allison JP
Semin Oncol; 2010 Oct; 37(5):473-84. PubMed ID: 21074063
[TBL] [Abstract][Full Text] [Related]
30. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
[TBL] [Abstract][Full Text] [Related]
31. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.
Sakamuri D; Glitza IC; Betancourt Cuellar SL; Subbiah V; Fu S; Tsimberidou AM; Wheler JJ; Hong DS; Naing A; Falchook GS; Fanale MA; Cabanillas ME; Janku F
Mol Cancer Ther; 2018 Mar; 17(3):671-676. PubMed ID: 29237802
[TBL] [Abstract][Full Text] [Related]
32. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
33. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
34. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
Bashey A; Medina B; Corringham S; Pasek M; Carrier E; Vrooman L; Lowy I; Solomon SR; Morris LE; Holland HK; Mason JR; Alyea EP; Soiffer RJ; Ball ED
Blood; 2009 Feb; 113(7):1581-8. PubMed ID: 18974373
[TBL] [Abstract][Full Text] [Related]
35. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
36. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
37. Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.
Lens M; Ferrucci PF; Testori A
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):105-13. PubMed ID: 18537753
[TBL] [Abstract][Full Text] [Related]
38. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
[TBL] [Abstract][Full Text] [Related]
39. Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky F; Middeke JM; Janz M; Lenz G; Witzens-Harig M; Bouabdallah R; La Rosée P; Viardot A; Salles G; Kim SJ; Kim TM; Ottmann O; Chromik J; Quinson AM; von Wangenheim U; Burkard U; Berk A; Schmitz N
Invest New Drugs; 2020 Oct; 38(5):1472-1482. PubMed ID: 32172489
[TBL] [Abstract][Full Text] [Related]
40. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
Morschhauser F; Leonard JP; Fayad L; Coiffier B; Petillon MO; Coleman M; Schuster SJ; Dyer MJ; Horne H; Teoh N; Wegener WA; Goldenberg DM
J Clin Oncol; 2009 Jul; 27(20):3346-53. PubMed ID: 19451441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
